Kanamycin Or Derivative Patents (Class 514/41)
  • Patent number: 9238670
    Abstract: This disclosure relates generally to aminoglycoside derivatives of Formula (I) as described herein. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating bacterial infections by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 19, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Anthony J. Ricci, Robert J. Greenhouse, Alan G. Cheng
  • Publication number: 20150126435
    Abstract: Disclosed are primers, probes, and single nucleotide polymorphisms (SNP) specific to a distinct subclones of the E. coli sequence type 131 (ST131). Also disclosed are methods and assay kits useful in detecting the presence of the distinct subtype of E. coli and methods of treating a subject suffering from an infection from a subclone of ST131.
    Type: Application
    Filed: July 2, 2013
    Publication date: May 7, 2015
    Inventors: Lance B. Price, Evgueni V. Sokurenko, James R. Johnson
  • Publication number: 20150110767
    Abstract: Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: PAUL B. SAVAGE, CARL A. GENBERG, MICHAEL D. TRIPLETT
  • Patent number: 8999942
    Abstract: In some aspects, the present invention provides aminoglycoside derivatives thereof that exhibit antibacterial activity. In some aspects, the aminoglycoside derivatives comprise compounds consisting of (a) an ammoglycoside group and (b) at least one hydrophobic carbamate and alkoxy group to the primary or secondary hydroxy position of the aminolvcoside group and salts thereof. Additionally, methods of treating and preventing bacterial infections using the aminoglycoside derivatives are also provided.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: April 7, 2015
    Assignee: University of Manitoba
    Inventors: Frank Schweizer, Smritilekha Bera, George Zhanel
  • Publication number: 20150087612
    Abstract: Compounds having the general structural formula (I) wherein X can be any element or compound that can form a coordination complex with phthalocyanine and wherein R1; R2, R3 and R4 are independently anionic moieties, or (II) wherein R1; R2, R3 and R4 are independently anionic moieties, are useful in the potentiation of antibiotic activity, and/or in inhibiting or delaying the development of resistance to antibiotics. R1; R2, R3 and R4 may be —S03-. The compounds may be administered to a subject in conjunction with an antibiotic. The antibiotic may be an activator of the SOS response, and may be a DNA gyrase inhibitor or a topoisomerase inhibitor. Compositions and dosage forms comprising the compounds are provided.
    Type: Application
    Filed: April 11, 2013
    Publication date: March 26, 2015
    Inventors: Clarence Ronald Geyer, Yu Luo
  • Patent number: 8980226
    Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 17, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: William Baker, David MacLeod
  • Publication number: 20150005249
    Abstract: A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following Structural Formula (A), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Inventors: Ryoichi Matsuda, Masataka Shiozuka, Akira Wagatsuma, Yoshikazu Takahashi, Daishiro Ikeda, Yoshiaki Nonomura, Masafumi Matsuo, Atsushi Nishida
  • Patent number: 8906868
    Abstract: The present invention relates to antimicrobial agents. Some embodiments include compounds, compositions, methods of preparation, and methods of treatment using new aminoglycosides and aminoglycoside derivatives.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: December 9, 2014
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: Tomasz W. Glinka, Olga Rodny
  • Publication number: 20140356457
    Abstract: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test com
    Type: Application
    Filed: April 7, 2014
    Publication date: December 4, 2014
    Applicant: UNIVERSITY OF GENEVA
    Inventors: Karl-Heinz KRAUSE, Botond BANFI
  • Publication number: 20140357591
    Abstract: Provided herein are antimicrobial conjugates of two antibiotic agents, exhibiting improved activity also against resistant bacteria, compared to each of the agents separately or their mixture, and having substantially no resistance emerged thereagainst, as well as processes for preparation the same, compositions containing the same, and uses thereof in medical treatments against pathogenic microorganisms. The disclosed antimicrobial conjugates are composed of aminoglycosides and non-ribosomal active antibiotics. Some of the antimicrobial conjugates are prepared via “click” chemistry.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventors: Timor BAASOV, Varvara Pokrovskaya, Valery Belakhov, Mariana Hainrichson
  • Publication number: 20140343005
    Abstract: The invention provides aqueous liquid pharmaceutical compositions comprising arbekacin and chloride ions. The compositions are well tolerable for use in a method for treatment or prevention of a disease of the upper or lower respiratory tract, wherein the composition is aerosolized and inhaled by the patient. Furthermore, the invention provides arbekacin hydrochloride.
    Type: Application
    Filed: August 3, 2012
    Publication date: November 20, 2014
    Applicants: PARI PHARMA GMBH, MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Manfred Keller, Yukihiro Yagi, Masashi Tanaka, Toshie Sugano, Kuniko Shoji, Nao Sano, Michael Hahn, Roman Egle
  • Patent number: 8889153
    Abstract: A compound comprising combination of an immunomodulator and to at least one anti-pathogenic agent for treating of facultative or strict infections caused by intracellular microorganisms, the components of the combination or association of substances of the invention, the immunomodulator (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance with antimicrobial properties can be administered either jointly, simultaneously, consecutively or sequentially, in an appropriate form, according to their chemical properties, and in a dose effective against microorganisms in human and animals.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: November 18, 2014
    Inventor: Iseu da Silva Nunes
  • Patent number: 8865665
    Abstract: The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present invention are analogues of kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: October 21, 2014
    Assignee: Utah State University
    Inventors: Cheng-Wei T. Chang, Jon Takemoto
  • Patent number: 8865664
    Abstract: Hydrophobically enhanced aminoglycosides have been prepared and shown to be effective antibacterial agents. These agents may be used in the treatment or prevention of various bacterial infections. Methods of preparing these agents also permit facile synthetic access. Formula (I).
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: October 21, 2014
    Assignee: University of Manitoba
    Inventors: Smritilekha Bera, George G. Zhanel, Frank Schweizer
  • Publication number: 20140255479
    Abstract: The present invention provides pharmaceutical compositions suitable for oral and methods of treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance bioavailability of at least one compound classified as BCS Class II, BCS Class III or BCS Class IV.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Inventors: Stephen M. Carl, John Stanley Vrettos, William Stern
  • Publication number: 20140256664
    Abstract: The present application discloses rapid Mycobacterium tuberculosis drug susceptibility utilizing real-time PCR of mycobacteriophage D29 DNA. One protocol involves culturing Tb isolates for 48 hours with and without drugs at critical concentrations, followed by incubation with 103 pfu/ml of D29 mycobacteriophage for 24 hours and then real-time PCR. Many drugs can be incubated instantly with Tb and phage. The change in phage DNA real-time PCR cycle threshold (Ct) between control Tb and Tb treated with drugs was calculated and correlated with conventional agar proportion drug susceptibility results. Specifically, 9 susceptible clinical isolates, 22 MDR, and 1 XDR Tb strains were used and Ct control?Ct drug cutoffs of between +0.3 and ?6.0 yielded 422/429 (98%) accurate results for the drugs tested. The Ct values correlated with isolate minimal inhibitory concentration (MIC) for most agents. This D29 qPCR assay offers a rapid, accurate, 1-3 day phenotypic drug susceptibility test.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 11, 2014
    Applicant: University of Virginia Patent Foundation
    Inventors: Eric R. Houpt, Kimberly A. Kelly, Suporn Pholwat
  • Patent number: 8809286
    Abstract: Provided herein are antimicrobial conjugates of two antibiotic agents, exhibiting improved activity also against resistant bacteria, compared to each of the agents separately or their mixture, and having substantially no resistance emerged thereagainst, as well as processes for preparation the same, compositions containing the same, and uses thereof in medical treatments against pathogenic microorganisms. The disclosed antimicrobial conjugates are composed of aminoglycosides and non-ribosomal active antibiotics. Some of the antimicrobial conjugates are prepared via “click” chemistry.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: August 19, 2014
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Timor Baasov, Varvara Pokrovskaya, Valery Belakhov, Mariana Hainrichson
  • Publication number: 20140228312
    Abstract: The present invention relates to a composition comprising: an antibiotic selected from the group consisting of an aminoglycoside antibiotic, a beta-lactam antibiotic, an ansamycin antibiotic, a macrolide antibiotic, a sulfonamide antibiotic, a quinolone antibiotic, an oxazolidinone antibiotic, a glycopeptide antibiotic, and a mixture thereof; and a fatty acid represented by formula (I), a stereoisomer, a salt or an ester thereof, wherein R1 is a substituted or unsubstituted aliphatic group.
    Type: Application
    Filed: October 1, 2012
    Publication date: August 14, 2014
    Inventors: Lianhui Zhang, Yinyue Deng
  • Patent number: 8791245
    Abstract: The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: July 29, 2014
    Assignee: Glycan Bioscience LLC
    Inventors: Warren Charles Kett, Yugang Chen
  • Publication number: 20140206606
    Abstract: The present invention provides compounds of formula (I), wherein G1 is oxygen; R1 is hydrogen; R2 is group P (P) L is a bond, methylene or ethylene; one of A1 and A2 is S, SO or SO2 and the other is —C(R4)R4—R3 is hydrogen or methyl; each R4 is independently hydrogen or methyl; Y1 is C—R6, CH or nitrogen; Y2 and Y3 are independently CH or nitrogen; wherein no more than two of Y1, Y2 and Y3 are nitrogen and wherein Y2 and Y3 are not both nitrogen; R5 is hydrogen, halogen, cyano, nitro, NH2, C1-C2alkyl, C1-C2haloalkyl, C3-C5cycloalkyl, C3-C5halocycloalkyl, C1-C2alkoxy, C1-C2haloalkoxy; R6 together with R5 forms a —CH?CH—CH?CH— bridge; X2 is C—X6 or nitrogen; X1, X3 and X6 are independently hydrogen, halogen or trihalomethyl, wherein at least two of X1, X3 and X6 are not hydrogen; X4 is trifluoromethyl, difluoromethyl or chlorodifluoromethyl.
    Type: Application
    Filed: August 24, 2012
    Publication date: July 24, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Jerome Yves Cassayre, Peter Renold, Thomas Pitterna, Myriem El Qacemi
  • Publication number: 20140200193
    Abstract: A biological thixotropic adhesive that contains dextrin, and at least a structural component that provides thixotropy to the adhesive, and optionally at least an antibiotic that is very useful to stimulate the process of healing of tissues in a patient, for example, to prevent anastomotic leaks of the gastrointestinal system, to affix a prosthesis in inguinal hernioplasties, in a patient and to oclude a fistula in a patient. The biological thixotropic dahesive also has anti-inflammatory properties and can be used with a fatty tissue patch.
    Type: Application
    Filed: November 30, 2011
    Publication date: July 17, 2014
    Inventor: Jorge Cueto García
  • Publication number: 20140194376
    Abstract: The present invention provides compounds of formula (I) wherein G1 is oxygen; R1 is hydrogen; R2 is group (P) L is a bond, methylene or ethylene; one of A1 and A2 is S, SO or SO2 and the other is —C(R4)R4—; R3 is hydrogen or methyl; each R4 is independently hydrogen or methyl; Y2 and Y3 are independently CH or nitrogen, wherein Y2 and Y3 are not both nitrogen; X2 is C—X6 or nitrogen; X1, X3 and X6 are independently hydrogen, halogen or trihalomethyl, wherein at least two of X1, X3 and X6 are not hydrogen; X4 is trifluoromethyl, difluoromethyl or chlorodifluoromethyl. The invention also provides intermediates useful for the preparation of compounds of formula (I), as well as methods of controlling insects, acarines, nematodes or molluscs using the compounds of formula (I).
    Type: Application
    Filed: August 24, 2012
    Publication date: July 10, 2014
    Applicant: SYNGENTA PARTICIPATIONS AG
    Inventors: Jerome Yves Cassayre, Peter Renold, Thomas Pitterna, Myriem El Qacemi
  • Patent number: 8765698
    Abstract: Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., HIV-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount of a read-through mediating agent sufficient to induce exogenous expression of an amount of retrocyclin nonapeptides in the mammalian cell.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: July 1, 2014
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Alexander M. Cole
  • Patent number: 8715623
    Abstract: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 6, 2014
    Assignee: Novartis AG
    Inventors: Thomas E. Tarara, Jeffry G. Weers, Geraldine Venthoye
  • Publication number: 20140107057
    Abstract: The present invention provides a combination product comprising a component A and a component B, wherein component A is a compound of formula (I) wherein A1, A2, L, p, R1, R2, R3, R4 and R5 are as defined in claim 1 and component B is a further therapeutic agent; wherein the combination product is for use in a method of therapeutic treatment.
    Type: Application
    Filed: May 30, 2012
    Publication date: April 17, 2014
    Applicant: Syngenta Participations AG
    Inventors: Jerome Yves Cassayre, Myriem El Qacemi
  • Patent number: 8679532
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: March 25, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Patent number: 8673348
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: March 18, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Patent number: 8673349
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: March 18, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Publication number: 20140044684
    Abstract: In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translation termination.
    Type: Application
    Filed: January 8, 2013
    Publication date: February 13, 2014
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard Mulligan, George J. Murphy
  • Publication number: 20140038914
    Abstract: This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof; wherein R1 to R4, R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof; and method of using same for reducing or reversing bacterial resistance to at least one aminoglycoside antibiotic.
    Type: Application
    Filed: January 17, 2012
    Publication date: February 6, 2014
    Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
    Inventors: Karine Auclair, Kenward Vong
  • Patent number: 8642075
    Abstract: A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: February 4, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Patent number: 8632804
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: January 21, 2014
    Assignee: Insmed Incorporated
    Inventor: Jeff Weers
  • Publication number: 20140018312
    Abstract: The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular or intracellular electron transport-deficient microbes and/or increase the antimicrobial activity of aminoglycoside antibiotics against their targets, and which are useful as antibacterial agents for treatment or prophylaxis of monomicrobiotic or polymicrobic bacterial infections or for the reduction of antibiotic resistance development in animals or in humans, or for use as antiseptics or agents for sterilization or disinfection.
    Type: Application
    Filed: February 15, 2012
    Publication date: January 16, 2014
    Applicant: SOCPRA SCIENCES ET GENIE, S.E.C.
    Inventors: François Malouin, Gabriel Mitchell, Kamal Bouarab, Eric Marsault, Felix Chagnon, Simon Boulanger, Isabelle Guay
  • Publication number: 20130338059
    Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.
    Type: Application
    Filed: December 22, 2011
    Publication date: December 19, 2013
    Applicant: Centre Hospitalier Universitaire Vaudois
    Inventors: Giuseppe Pantaleo, Alexandre Harari, Matthieu Perreau
  • Patent number: 8586552
    Abstract: Aminoglycoside antibiotics of the formula are disclosed. The compounds are useful for treating bacterial infections, particularly infections resistant to known antibiotics.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: November 19, 2013
    Assignee: SelectX Pharmaceuticals, Inc.
    Inventors: Michael G. Chaparian, Michael Brady, Scott Moe, Babu Rao Renikuntla, Srinivas Gadthula, Srinivasarao Meneni, Venkata Sai Prakash Chaturvedula
  • Publication number: 20130303473
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 14, 2013
    Applicant: NOVALIQ GmbH
    Inventor: Clive G. Wilson
  • Publication number: 20130287866
    Abstract: Use of nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, such as peripheral vascular disease. The nitric oxide amino acid esters may be co-administered with an antimicrobial in topical or transdermal compositions for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation.
    Type: Application
    Filed: October 26, 2011
    Publication date: October 31, 2013
    Applicant: ORAL DELIVERY TECHNOLOGY LTD.
    Inventor: Michael Farber
  • Patent number: 8507454
    Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: August 13, 2013
    Assignee: Novartis AG
    Inventors: Robert J Speirs, Barbara A Schaeffler, Peter B Challoner
  • Publication number: 20130171210
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.
    Type: Application
    Filed: March 1, 2013
    Publication date: July 4, 2013
    Applicant: MICROBION CORPORATION
    Inventor: MICROBION CORPORATION
  • Publication number: 20130137652
    Abstract: This invention relates to the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof in combination with an aminoglycoside antimicrobial agent for the prevention and/or treatment of microbial infections.
    Type: Application
    Filed: August 5, 2011
    Publication date: May 30, 2013
    Applicant: HELPERBY THERAPEUTICS LIMITED
    Inventors: Yanmin Hu, Anthony R.M. Coates
  • Patent number: 8426373
    Abstract: A pharmaceutical composition containing at least one ?-lactam antibiotic, at least one ion-chelating agent, at least one buffer component, and at least one aminoglycoside antibiotic.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: April 23, 2013
    Inventor: Hesheng Zhang
  • Publication number: 20130096078
    Abstract: Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, Streptomyces<i/> species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.
    Type: Application
    Filed: October 14, 2010
    Publication date: April 18, 2013
    Applicant: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION
    Inventors: Yeo Joon Yoon, Sung Ryeol Park, Je Won Park, Jae Kyung Sohng
  • Patent number: 8409549
    Abstract: A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 ?, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: April 2, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: William Baker, David MacLeod
  • Publication number: 20130071469
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Application
    Filed: November 13, 2012
    Publication date: March 21, 2013
    Applicant: Insmed Incorporated
    Inventor: Insmed Incorporated
  • Publication number: 20130064883
    Abstract: A system for treating or providing prophylaxis against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Application
    Filed: November 1, 2012
    Publication date: March 14, 2013
    Inventor: Insmed Incorporated
  • Publication number: 20130058983
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.
    Type: Application
    Filed: August 3, 2012
    Publication date: March 7, 2013
    Inventor: Brett Hugh James Baker
  • Publication number: 20130052260
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Application
    Filed: October 30, 2012
    Publication date: February 28, 2013
    Applicant: Insmed Incorporated
    Inventor: Insmed Incorporated
  • Publication number: 20130053337
    Abstract: Guanadinylated aminoglycoside-lipid conjugates are prepared. Such conjugates may comprise an aminoglycoside such as an aminoglyucoside antibiotic like neomycin or kanamycin, at least one guanidino group attached to a primary or secondary carbon atom of the aminoglyucoside group and at least one lipid group attached through a bond or a linker to a branched carbon atom of the aminoglycoside. These conjugates exhibit improve antibacterial activity and may be used in conjunction with another antibiotic.
    Type: Application
    Filed: March 4, 2011
    Publication date: February 28, 2013
    Applicant: UNIVERSITY OF MANITOBA
    Inventors: Frank Schweizer, Smritilekha Bera, George Zhanel
  • Patent number: 8377896
    Abstract: The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: February 19, 2013
    Assignee: Isis Pharmaceuticals, Inc
    Inventors: Michael T. Migawa, Xiaojing Wang, Eric E. Swayze, Richard H. Griffey
  • Publication number: 20130028960
    Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.
    Type: Application
    Filed: June 19, 2012
    Publication date: January 31, 2013
    Applicant: Insmed Incorporated
    Inventor: Jeff Weers